A growing number of users of GLP-1 weight-loss medications are finding themselves at a crossroads as initial dramatic results begin to stall, raising questions about cost, long-term use, and emerging alternatives.
One such case involves a woman who says her experience with Mounjaro transformed both her body and mental wellbeing, but has now left her reconsidering her next step as her progress levels off.
Dramatic Early Results on Prescription Injection
After beginning treatment last year, she reported a rapid reduction in appetite and a significant decrease in “food noise” — the constant cravings that previously drove her eating habits.
Within six months, she says she lost around two stone, bringing her weight down to approximately 11.5 stone.
The improvement, she explains, had a noticeable effect on her overall health and confidence, leading her to continue the medication at a reduced maintenance dose of 2.5mg administered weekly.
The injections, delivered subcutaneously into abdominal fat, became a routine part of her week as she sought to maintain her new weight.
Progress Stalls Despite Continued Treatment
However, over the past half-year, the expected downward trend on the scales has stopped.
Despite continued use of the drug, her weight has remained unchanged.
Although she acknowledges being significantly lighter than she has been in years, she notes that at 5ft 7in her body mass index still places her in the “overweight” category according to NHS guidelines.
The stagnation has led to frustration, particularly given the financial commitment of roughly £180 per month for private prescriptions.
With no further weight loss occurring, she estimates she is now spending more than £2,000 annually without measurable benefit.
Considering Dose Changes and New Experimental Alternatives
Faced with a plateau, she is now weighing two options: increasing her Mounjaro dosage at additional cost or switching to a newer experimental drug informally referred to as the “Godzilla jab.”
The compound, retatrutide, has shown promising results in clinical trials, with participants reportedly achieving significantly higher weight loss than those using tirzepatide-based treatments such as Mounjaro.
Some studies have suggested reductions exceeding a quarter of body weight over extended periods.
Unlike currently licensed medications, however, retatrutide remains unapproved for prescription use in the UK, with regulatory clearance not expected until the latter part of the decade.
The Rise of a “Grey Market” Drug Economy
Despite its unlicensed status, retatrutide has already developed a presence online.
Reports suggest it is being distributed through unofficial channels, often marketed under the guise of “research use only” products.
These versions are not regulated by medicines authorities, raising concerns about quality control, storage conditions, and accurate dosing.
Nevertheless, the accessibility and relatively lower cost compared with private prescriptions have contributed to growing interest among potential users.
Some social media influencers have also been promoting their experiences with the drug, sharing dramatic weight-loss claims and directing followers toward unofficial suppliers.
Social Media Influence and Normalisation Concerns
Experts studying illicit pharmaceutical markets say platforms such as TikTok and online forums are playing a significant role in normalising the use of unlicensed peptides.
Researchers warn that anecdotal success stories can create a false sense of safety, encouraging users to experiment without medical supervision.
Affiliate marketing and informal referral networks are also believed to be accelerating demand.
The combination of persuasive influencer content and easy online access has led to what some academics describe as a “rapidly expanding and poorly understood” market.
Health Risks and Uncertainty Around Dosage
Medical and criminology researchers caution that the safety profile of retatrutide is not yet fully established.
While expected side effects are similar to other GLP-1 drugs — including nausea, constipation, and gastrointestinal distress — early observations suggest potentially stronger reactions at higher doses.
Reports from informal user communities describe additional concerns such as elevated heart rate, anxiety, sleep disruption, and in some cases severe panic symptoms.
A further complication is inconsistent dosing. Products sold outside regulated systems may vary in strength or quality, increasing the risk of under- or over-dosing when users adjust intake based on perceived results.
A Personal Decision to Wait
Despite growing interest in experimental alternatives, the patient behind this account says she is unwilling to take risks with unregulated medications.
While acknowledging the pressure and appeal created by social media discussions, she has decided to continue with medically approved treatment pathways for now, preferring to wait for fully licensed options rather than experiment with uncertain compounds.
